Trial Profile
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms SHIELD-4
- Sponsors GlaxoSmithKline; GSK
- 20 Oct 2014 Results published in a ChemoCentryx media release.
- 20 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
- 07 Feb 2014 Actual patient number changed from 253 to 255 as reported by ClinicalTrials.gov.